Association Between Medicare and FDA Policies and Prior Authorization Requirements for Buprenorphine Products in Medicare Part D Plans.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 31287514.
- Also identified by DOI 10.1001/jama.2019.6581 and PMC identifier 6618771.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This study describes changes in the proportion of Medicare Part D plans requiring prior authorization for buprenorphine products before and after a 2017 FDA rquirement that the drug’s label emphasize the importance of drug treatment of opioid use disorder.
Medical subject headings
- Buprenorphine
- Government Regulation
- Insurance Coverage
- Medicare Part D
- Prior Authorization
- United States Food and Drug Administration